The recent flu pandemic has once more provided urgency for the development and assessment of influenza antiviral chemotherapy. During the last decade a great deal of valuable data have been obtained from the use of oseltamivir in different human populations under various circumstances, including information on the significant problem of antiviral resistance. This Supplement rehearses many of the key findings from the clinical trials to date. The scholarly reviews are by four authors who are all international experts with direct experience of oseltamivir. As well as providing some insight into current and planned lines of investigation, the conclusions they draw will help to inform debate on the further use of oseltamivir. Furthermore, the articles should provide an important source of background information to enlighten trials with future novel influenza antiviral compounds.
